Efficacy and safety of erlotinib combined with bevacizumab in the treatment of non-small cell lung cancer: A systematic review and meta-analysis
K Zhou, S Zhao, W Guo, L Ding - Medicine, 2020 - journals.lww.com
Background: Non-small cell lung cancer (NSCLC) has a poor prognosis despite
conventional treatments of surgery, radiotherapy, and chemotherapy. Small-molecule …
conventional treatments of surgery, radiotherapy, and chemotherapy. Small-molecule …
Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials
B Zhao, W Zhang, D Yu, J Xu, Y Wei - Lung Cancer, 2018 - Elsevier
Objectives A role for erlotinib and bevacizumab as single agents has been established in
the treatment of non-small cell lung cancer (NSCLC). However, the efficacy and safety of …
the treatment of non-small cell lung cancer (NSCLC). However, the efficacy and safety of …
Comparing efficacy of erlotinib and bevacizumab combination with erlotinib monotherapy in patients with advanced non-small cell lung cancer (NSCLC): A systematic …
P Sakharkar, S Kurup - Diseases, 2023 - mdpi.com
The objective of this systematic review and meta-analysis was to assess and contrast the
efficacy and safety of combining erlotinib and bevacizumab with erlotinib alone in the …
efficacy and safety of combining erlotinib and bevacizumab with erlotinib alone in the …
Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta …
S Zhang, X Mao, H Wang, F Cai, J Xu - BMJ open, 2016 - bmjopen.bmj.com
Objectives Bevacizumab and erlotinib inhibit different tumour growth pathways, and both
exhibit beneficial effects in the treatment of non-small-cell lung cancer (NSCLC). However …
exhibit beneficial effects in the treatment of non-small-cell lung cancer (NSCLC). However …
[HTML][HTML] A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous …
T Ciuleanu, CM Tsai, CJ Tsao, J Milanowski… - Lung Cancer, 2013 - Elsevier
Background Molecularly targeted agents for non-small cell lung cancer (NSCLC) can
provide similar efficacy to chemotherapy without chemotherapy-associated toxicities …
provide similar efficacy to chemotherapy without chemotherapy-associated toxicities …
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of …
W Deng, K Wang, Y Jiang, D Li, C Bao, J Luo, L Liu… - BMJ open, 2022 - bmjopen.bmj.com
Objectives Combination treatment with erlotinib plus bevacizumab has the potential to
become a standard treatment regimen for patients with epidermal growth factor receptor …
become a standard treatment regimen for patients with epidermal growth factor receptor …
Emerging drugs for non-small-cell lung cancer
E Felip, M Santarpia, R Rosell - Expert opinion on emerging drugs, 2007 - Taylor & Francis
Non-small-cell lung cancer (NSCLC) accounts for 80% of all lung cancer cases and is the
leading cause of cancer mortality. Despite the optimization of chemotherapy regimens …
leading cause of cancer mortality. Despite the optimization of chemotherapy regimens …
Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment …
L Sun, JT Ma, SL Zhang, HW Zou, CB Han - Medical Oncology, 2015 - Springer
The meta-analysis evaluated the efficacy and safety of chemotherapy or tyrosine kinase
inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors …
inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors …
Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis
S Batson, SA Mitchell, R Windisch… - OncoTargets and …, 2017 - Taylor & Francis
Introduction The introduction of epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs) has improved the outlook for patients with advanced non-small-cell lung …
(EGFR-TKIs) has improved the outlook for patients with advanced non-small-cell lung …
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double …
Background Bevacizumab and erlotinib target different tumour growth pathways with little
overlap in their toxic-effect profiles. On the basis of promising results from a phase 1/2 trial …
overlap in their toxic-effect profiles. On the basis of promising results from a phase 1/2 trial …
相关搜索
- lung cancer meta analysis
- efficacy and safety meta analysis
- efficacy and safety lung cancer
- bevacizumab in the treatment meta analysis
- lung cancer erlotinib alone
- erlotinib alone meta analysis
- safety of erlotinib meta analysis
- efficacy and safety of erlotinib
- efficacy of erlotinib bevacizumab combination
- efficacy of erlotinib meta analysis
- erlotinib in combination meta analysis
- erlotinib monotherapy meta analysis
- combination with bevacizumab meta analysis
- chemotherapy alone meta analysis
- erlotinib monotherapy bevacizumab combination